Cargando…
Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer
BACKGROUND: Well over a quarter of human breast cancers are ErbB2-driven and constitute a distinct subtype with substantially poorer prognosis. Yet, there are substantial gaps in our understanding of how ErbB2 tyrosine kinase activity unleashes a coordinated program of cellular and extracellular alt...
Autores principales: | Ortega-Cava, Cesar F., Raja, Srikumar M., Laiq, Zenab, Bailey, Tameka A., Luan, Haitao, Mohapatra, Bhopal, Williams, Stetson H., Ericsson, Aaron C., Goswami, Rasna, Dimri, Manjari, Duan, Lei, Band, Vimla, Naramura, Mayumi, Band, Hamid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243085/ https://www.ncbi.nlm.nih.gov/pubmed/22190871 http://dx.doi.org/10.4103/1477-3163.90443 |
Ejemplares similares
-
A Comprehensive, Multi-Scale Dynamical Model of ErbB Receptor Signal Transduction in Human Mammary Epithelial Cells
por: Helikar, Tomáš, et al.
Publicado: (2013) -
Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance
por: Bailey, Tameka A., et al.
Publicado: (2011) -
Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988) -
CHIP/STUB1 Ubiquitin Ligase Functions as a Negative Regulator of ErbB2 by Promoting Its Early Post-Biosynthesis Degradation
por: Luan, Haitao, et al.
Publicado: (2021) -
Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition
por: Raja, Srikumar M., et al.
Publicado: (2016)